BRCA1-associated breast cancers are associated with particular features such as early onset, poor histological differentiation, and hormone receptor negativity. Previous studies conducted in Taiwanese population showed that the mutation of BRCA1 gene does not play a significant role in the occurrence of breast cancer. The present study explored methylation of BRCA1 promoter and its relationship to clinical features and outcome in Taiwanese breast cancer patients. Tumor specimens from a cohort of 139 early-stage breast cancer patients were obtained during surgery before adjuvant treatment for DNA extraction. Methylation of BRCA1 promoter region was determined by methylation-specific PCR and the results were related to clinical features and outcome of patients using statistical analysis. Methylation of the BRCA1 promoter was detected in 78 (56%) of the 139 tumors. Chi-square analysis indicated that BRCA1 promoter methylation correlated significantly with triple-negative (ER-/PR-/HER2-) status of breast cancer patients (p = 0.041). The Kaplan-Meier method showed that BRCA1 promoter methylation was significantly associated with poor overall survival (p = 0.026) and disease-free survival (p = 0.001). Multivariate analysis which incorporated variables of patients' age, tumor size, grade, and lymph node metastasis revealed that BRCA1 promoter methylation was associated with overall survival (p = 0.027; hazard ratio, 16.38) and disease-free survival (p = 0.003; hazard ratio, 12.19) [corrected].Our findings underscore the clinical relevance of the methylation of BRCA1 promoter in Taiwanese patients with early-stage breast cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566056 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0056256 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Validation and Performance of Quantitative BRCA1 and RAD51C Promoter Hypermethylation Testing in Breast and Ovarian Cancers.
J Mol Diagn
December 2024
XING Genomic Services, Sinnamon Park, Queensland, Australia; Translational Medicine, AstraZeneca, Cambridge, United Kingdom.
Poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors represent a significant advancement in the treatment of epithelial ovarian cancer, triple-negative breast cancer, pancreatic cancer, and castrate-resistant prostate cancer, and they are poised to improve treatment in an increasing number of other cancer types. PARP inhibitor efficacy as monotherapy has been primarily observed in tumors with deleterious genetic variants in genes involved in the homologous recombination repair pathway. Tumors without these variants have also been shown to respond; notably, those with hypermethylation at all alleles of the BRCA1 or RAD51C promoter can respond to PARP inhibitors.
View Article and Find Full Text PDFBRCA1 & BRCA2 methylation as a prognostic and predictive biomarker in cancer: Implementation in liquid biopsy in the era of precision medicine.
Clin Epigenetics
December 2024
Laboratory of Pharmacology, Department of Medicine, Democritus University of Thrace, 68100, Alexandroupolis, Greece.
Article Synopsis
- BRCA1 and BRCA2 are tumor suppressor genes critical for repairing DNA damage through the Homologous Recombination pathway, and mutations in these genes are linked to higher risks of breast and ovarian cancers.
- Methylation of BRCA1/2 promoters can create a "BRCAness" phenotype, indicating HR deficiency in tumors, even when BRCA mutations are absent, and this methylation may serve as a valuable biomarker for predicting responsiveness to therapies like PARP inhibitors.
- The review emphasizes the need for further research into BRCA1/2 methylation as a predictive tool in cancer treatment, suggesting it could significantly enhance prognosis and treatment strategies across various cancer types.
Olaparib promotes FABP4 expression and reduces antitumor effect in ovarian cancer cells with a mutation.
Oncol Lett
February 2025
Department of Gynecological Oncology, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China.
Olaparib (AZD2281) is used as a first-line maintenance treatment for patients with ovarian cancer (OC) with a breast cancer susceptibility gene () mutation. Fatty acid binding protein 4 (FABP4) may serve an important role in cancer, but its role in olaparib-treated OC with a mutation requires further clarification. To explore the function of FABP4 and enhance the efficacy of AZD2281 in OC, cell counting kit-8, cell apoptosis, cell cycle, colony formation, cell transfection, western blotting, reverse transcription-quantitative polymerase chain reaction, chromatin immunoprecipitation, seahorse and reactive oxygen species assays were performed.
View Article and Find Full Text PDFLetter to the Editor in response to paper "BRCA1 promoter methylation in triple-negative breast cancer……" by K Daster et al.
Breast Cancer Res Treat
November 2024
Haukeland University Hospital, University of Bergen, Bergen, Norway.
Brca1 haploinsufficiency promotes early tumor onset and epigenetic alterations in a mouse model of hereditary breast cancer.
Nat Genet
December 2024
Department of Cell Biology, Harvard Medical School, Boston, MA, USA.
Article Synopsis
- Germline BRCA1 mutation carriers have a high breast cancer risk, but the reasons for this increased risk are not fully understood.
- Researchers used a genetically engineered mouse model to show that the early onset of tumors in BRCA1 heterozygous mice can't be explained by the traditional "two-hit" hypothesis alone.
- Advanced techniques like single-cell RNA sequencing revealed distinct chromatin alterations in normal Brca1 heterozygous cells, hinting at epigenetic changes that might promote cancer, with specific transcription factors identified as key players in tumor development.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!